Search results
Results from the WOW.Com Content Network
Ankylosing spondylitis (AS) is a type of arthritis from the disease spectrum of axial spondyloarthritis. [5] It is characterized by long-term inflammation of the joints of the spine, typically where the spine joins the pelvis. [2] With AS, eye and bowel problems—as well as back pain—may occur. [2]
Ankylosing spondylitis is a genetic disease with identifiable marks, tends to start showing signs in adolescence or young adulthood, is more likely to affect the lumbar spine, and affects organs. DISH has no indication of a genetic link, is primarily thoracic and does not affect organs other than the lungs, and only indirectly due to the fusion ...
Since the disease ankylosing spondylitis was still defined by the Modified New York criteria of 1984, there was the need to find a new disease term that would also include the less severe forms or early onset of ankylosing spondylitis. This expression was found in the umbrella term axial spondyloarthritis.
Download QR code; Print/export Download as PDF; Printable version; In other projects Wikimedia Commons; Wikidata item; ... Pages in category "Ankylosing spondylitis"
They publish WebMD the Magazine, a patient-directed publication distributed bimonthly free of charge to 85 percent of physician waiting rooms. [13] Medscape is a professional portal for physicians and has training materials, a drug database, and clinical information on 30 medical specialty areas and more than 30 physician discussion boards. [ 14 ]
The BASDAI or Bath Ankylosing Spondylitis Disease Activity Index is a validated diagnostic test which allows a physician, usually a rheumatologist, to determine the effectiveness of a current drug therapy, or the need to institute a new drug therapy for the treatment of Ankylosing spondylitis (AS).
Upgrade to a faster, more secure version of a supported browser. It's free and it only takes a few moments:
Pharmaceutical companies began utilizing the ASQoL to test the effectiveness of newly developed TNF inhibitors, which aid in the treatment of ankylosing spondylitis. [5] [6] Abbott has utilized the ASQoL to evaluate the impact of adalimumab [7] [8] and other organizations like Wyeth and the Medical Research Council have used it to evaluate the effect of etanercept.